{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:59:07Z","timestamp":1771952347260,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pfizer Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06838-z","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:05:50Z","timestamp":1770275150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance"],"prefix":"10.1007","volume":"105","author":[{"given":"Jae-Ho","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwai Han","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juwon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Mee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"1","key":"6838_CR1","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet 381(1):1943\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(12)62187-4","journal-title":"Lancet"},{"key":"6838_CR2","unstructured":"American Cancer Society, Cancer Facts &, Figs. 2025, Atlanta GA: American Cancer Society (2025). [Online]. Available: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf"},{"key":"6838_CR3","unstructured":"Korea Central Cancer Registry (2024) Annual report of cancer statistics in Korea in 2022. Ministry of Health and Welfare, Republic of Korea. [Online]. Available: https:\/\/www.mohw.go.kr\/boardDownload.es?bid=0043&list_no=1486203&seq=1"},{"issue":"30","key":"6838_CR4","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7(30):e577. https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"6838_CR5","doi-asserted-by":"crossref","unstructured":"Thomas DA, Kantarjian H, Smith TL (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 86(7):1216\u20131230. https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"6838_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"4","author":"A Oriol","year":"2010","unstructured":"Oriol A, Vives S, Hern\u00e1ndez-Rivas JM et al (2010) Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica 4:589\u2013596","journal-title":"Haematologica"},{"key":"6838_CR7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J et al (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120:2032\u20132041","journal-title":"Blood"},{"key":"6838_CR8","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","volume":"21","author":"E Tavernier","year":"2007","unstructured":"Tavernier E, Boiron JM, Huguet F et al (2007) Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:1907\u20131914","journal-title":"Leukemia"},{"key":"6838_CR9","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas D, Ravandi F et al (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113:3186\u20133191","journal-title":"Cancer"},{"key":"6838_CR10","doi-asserted-by":"crossref","unstructured":"Rubinstein JD, O\u2019Brien MM (2023) Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.\u00a0Front Immunol\u00a014:1237738. [Online]. Available: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10435844\/pdf\/fimmu-14-1237738.pdf","DOI":"10.3389\/fimmu.2023.1237738"},{"issue":"21","key":"6838_CR11","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.35505","volume":"130","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian HM et al (2024) Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions,. Cancer 130(21):3631\u20133646","journal-title":"Cancer"},{"issue":"1","key":"6838_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","volume":"17","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Kantarjian H (2024) Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol 17(1):32. https:\/\/doi.org\/10.1186\/s13045-024-01552-7","journal-title":"J Hematol Oncol"},{"issue":"9","key":"6838_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","volume":"19","author":"PA Brown","year":"2021","unstructured":"Brown PA et al (2021) Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(9):1079\u20131109","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"6838_CR14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/14712598.2017.1387244","volume":"17","author":"A Tvito","year":"2017","unstructured":"Tvito A, Rowe JM (2017) Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia,. Expert Opin Biol Ther 17(12):1557\u20131564. https:\/\/doi.org\/10.1080\/14712598.2017.1387244","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"6838_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN (2017) Inotuzumab ozogamicin: first global approval,. Drugs 77(14):1603\u20131610. https:\/\/doi.org\/10.1007\/s40265-017-0802-5","journal-title":"Drugs"},{"key":"6838_CR16","unstructured":"Lee E-K et al (2019) Drug approval report. Ministry of Food and Drug Safety, Republic of Korea, July 2020. [Online]. Available: https:\/\/www.mfds.go.kr\/eng\/brd\/m_19\/down.do?brd_id=eng0004&seq=70435&data_tp=A&file_seq=1"},{"key":"6838_CR17","doi-asserted-by":"crossref","unstructured":"Kantarjian HM et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.\u00a0New Engl J Med\u00a0375(8):740\u2013753. [Online]. Available: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5594743\/pdf\/nihms858972.pdf","DOI":"10.1056\/NEJMoa1509277"},{"issue":"8","key":"6838_CR18","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS et al (2017) Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 4(8):e387\u2013e398. https:\/\/doi.org\/10.1016\/S2352-3026(17)30103-5","journal-title":"Lancet Haematol"},{"issue":"3","key":"6838_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/cam4.4390","volume":"11","author":"F Ravaioli","year":"2022","unstructured":"Ravaioli F, Marconi G, Martinelli G et al (2022) Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. Cancer Med 11(3):618\u2013629. https:\/\/doi.org\/10.1002\/cam4.4390","journal-title":"Cancer Med"},{"issue":"5","key":"6838_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jtct.2023.01.017","volume":"29","author":"V Agrawal","year":"2023","unstructured":"Agrawal V, Pourhassan H, Tsai NC et al (2023) Post-transplantation sinusoidal obstruction syndrome in adult patients with B cell acute lymphoblastic leukemia treated with pretransplantation inotuzumab. Biol Blood Marrow Transplant 29(5):314\u2013320. https:\/\/doi.org\/10.1016\/j.jtct.2023.01.017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"6838_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"Selim Corbacioglu","year":"2019","unstructured":"Corbacioglu Selim et al (2019) Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant 25(7):1271\u20131280. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"6838_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","volume":"53","author":"Partow Kebriaei","year":"2018","unstructured":"Kebriaei Partow et al (2018) Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant 53(4):449\u2013456. https:\/\/doi.org\/10.1038\/s41409-017-0019-y","journal-title":"Bone Marrow Transplant"},{"key":"6838_CR23","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","volume":"109","author":"S Kayser","year":"2024","unstructured":"Kayser S et al (2024) Impact of inotuzumab Ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease. Haematologica. 1 May 109:5 1385\u20131392. https:\/\/doi.org\/10.3324\/haematol.2023.284310","journal-title":"1 May"},{"key":"6838_CR24","doi-asserted-by":"crossref","unstructured":"Kantarjian HM et al (2019) Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow\u2010up from the randomized, phase 3 INO\u2010VATE study.\u00a0Cancer\u00a0125(14):2474\u20132487. [Online]. Available: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6618133\/pdf\/CNCR-125-2474.pdf","DOI":"10.1002\/cncr.32116"},{"key":"6838_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s43441-019-00021-5","volume":"54","author":"G Ball","year":"2020","unstructured":"Ball G et al (2020) A framework for safety evaluation throughout the product development life-cycle. Therapeutic Innov Regul Sci 54:821\u2013830","journal-title":"Therapeutic Innov Regul Sci"},{"issue":"Supplement 1","key":"6838_CR26","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1182\/blood-2024-212010","volume":"144","author":"J-H Yoon","year":"2024","unstructured":"Yoon J-H et al (2024) Real-world experience of efficacy and toxicity issues of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia. Blood 144(Supplement 1):5880\u20135880","journal-title":"Blood"},{"issue":"8","key":"6838_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.clml.2020.03.004","volume":"20","author":"T Badar","year":"2020","unstructured":"Badar T et al (2020) Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk 20(8):556\u2013560. e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6838_CR28","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2024-204581","volume":"144","author":"E Jiang","year":"2024","unstructured":"Jiang E, Lv M, Cao Y (2024) Safety and efficacy results of dose-adjusted inotuzumab ozogamicin in adults with B cell acute lymphoblastic leukemia: a retrospective single-center experience. Blood 144:1422","journal-title":"Blood"},{"key":"6838_CR29","unstructured":"Papayannidis C, Petracci E, Zappasodi P et al. INO-CD22: a multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed\/refractory acute lymphoblastic leukemia"},{"issue":"3","key":"6838_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/ejh.14031","volume":"111","author":"A Torrent","year":"2023","unstructured":"Torrent A, Morgades M, Garc\u00eda-Calduch O et al (2023) Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain. Eur J Haematol 111(3):485\u2013490. https:\/\/doi.org\/10.1111\/ejh.14031","journal-title":"Eur J Haematol"},{"issue":"19","key":"6838_CR31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2217\/fon-2022-1314","volume":"19","author":"T Moribe","year":"2023","unstructured":"Moribe T, Xu L, Tajima K, Yonemoto N (2023) Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan. Future Oncol 19(19):1343\u20131356. https:\/\/doi.org\/10.2217\/fon-2022-1314","journal-title":"Future Oncol"},{"key":"6838_CR32","doi-asserted-by":"publisher","unstructured":"Shetty A, Dubey A, Matcheswala A, Bangera S (2023) Pharmacovigilance systems and strategies: importance of post-marketing surveillance for ensuring drug safety and patient health in Europe, united States, and India. Authorea Preprints. https:\/\/doi.org\/10.22541\/au.167730302.27488138\/v1","DOI":"10.22541\/au.167730302.27488138\/v1"},{"key":"6838_CR33","doi-asserted-by":"crossref","unstructured":"Chakraborty A, Venkatraman JV (2023) Pharmacovigilance through phased clinical trials, post-marketing surveillance and ongoing life cycle safety. In: Jagadeesh G, Balakumar P, Senatore F (eds). The quintessence of basic and clinical research and scientific publishing. Springer, pp 427\u2013442","DOI":"10.1007\/978-981-99-1284-1_27"},{"key":"6838_CR34","unstructured":"Health UD, Services H (2010) National cancer institute (nci) common terminology criteria for adverse events (CTCAE), version 4.03. NIH Publication"},{"key":"6838_CR35","unstructured":"Network NCC (2016) NCCN Guidelines Acute Lymphoblastic Leukemia v2. 2016. Fort Washington, PA: National Comprehensive Cancer Network"},{"issue":"Supplement 1","key":"6838_CR36","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood-2022-171189","volume":"140","author":"J Senapati","year":"2022","unstructured":"Senapati J et al (2022) Predictors of veno-occlusive disease (VOD) of the liver in patients treated with Inotuzumab Ozogamicin (InO) containing regimen in B-cell acute lymphoblastic leukemia. Blood 140(Supplement 1):3155\u20133157","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06838-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06838-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06838-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:04:44Z","timestamp":1771949084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06838-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6838"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06838-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards at all participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}